Clinical Trials
13 trialsNCT07602842 2026-05-22
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
InduPro, Inc.
Phase 1/2 Not yet recruiting
NCT07583316 2026-05-13
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT07583914 2026-05-13
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
West China Hospital
Phase 1 Not yet recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT07361133 2026-04-16
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
Phase 2 Not yet recruiting
NCT07521670 2026-04-13
STRAP
National Cancer Centre, Singapore
Phase 2 Not yet recruiting
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT07252661 2025-11-28
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
Phase 1 Not yet recruiting
NCT06815705 2025-02-07
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase NA Not yet recruiting
NCT06719479 2024-12-05
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
SUNHO(China)BioPharmaceutical CO., Ltd.
Phase 2/3 Not yet recruiting
NCT06383507 2024-04-25
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Zhejiang University
Phase 1 Not yet recruiting
NCT05582590 2024-01-16
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
NexImmune Inc.
Phase 1 Not yet recruiting
NCT04890522 2021-05-18
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
Sun Yat-sen University
Phase 2/3 Not yet recruiting